Australia's National Cannabis Prevention and Information Centre (NCPIC) states that the buds (flowers) of the female cannabis plant contain the highest concentration of THC, followed by the leaves. The stalks and seeds have "much lower THC levels". The UN states that leaves can contain ten times less THC than the buds, and the stalks one hundred times less THC.
With your seed or plant acquisition request, you must submit a copy of your industrial hemp growers license, the industrial hemp license for the firm providing the seed and third party test results showing the variety is below the .3%THC threshold. If you want to grow and sell clones, you must provide documentation of permission from the source that allows for replication of those genetics. All seed and clones being brought into the state or leaving the state must be shipped or brought DIRECTLY to the Tennessee Department of agriculture for inventory. Movement permits are required to track the purchase or movement of industrial hemp seed, seedling and clones (viable material).
During the period from 1937 to the late 60s, the U.S. government understood and acknowledged that industrial hemp and marijuana were distinct varieties of the Cannabis plant. Hemp was no longer officially recognized as distinct from marijuana after the passage of the Controlled Substances Act (CSA) of 1970. This is despite the fact that a specific exemption for hemp was included in the CSA under the definition of marijuana. The recent federal court case HIA vs DEA has re-established acknowledgement of distinct varieties of Cannabis, and supports the exemption for non-viable seed and fiber and any products made from them.
A cross-sectional survey of cancer patients seen at the Seattle Cancer Care Alliance was conducted over a 6-week period between 2015 and 2016. In Washington State, Cannabis was legalized for medicinal use in 1998 and for recreational use in 2012. Of the 2,737 possible participants, 936 (34%) completed the anonymous questionnaire. Twenty-four percent of patients considered themselves active Cannabis users. Similar numbers of patients inhaled (70%) or used edibles (70%), with dual use (40%) being common. Non–mutually exclusive reasons for Cannabis use were physical symptoms (75%), neuropsychiatric symptoms (63%), recreational use/enjoyment (35%), and treatment of cancer (26%). The physical symptoms most commonly cited were pain, nausea, and loss of appetite. The majority of patients (74%) stated that they would prefer to obtain information about Cannabis from their cancer team, but less than 15% reported receiving information from their cancer physician or nurse.
The applicant, including all corporate officers, must be fingerprinted at a law enforcement agency. The law enforcement agency, not the applicant, must send the fingerprint sheet to the Department (80-18-103, MCA). Most local law enforcement offices provide fingerprinting services. The completed application and copy of the law enforcement submitted fingerprints will be submitted for DEA review and approval. The DEA may place additional requirements on the Department or the applicant for participation or continuation of the program. At the end of the licensure, program participants must submit an agricultural/agronomic report regarding their experience with their hemp crop. The report shall include the approximate yield in pounds per acre and the method used to devitalize the seed. All seed must be devitalized after harvest and no seed production for future planting is allowed under the Montana Industrial Hemp Pilot Program.
The U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and activities on the basis of race, color, national origin, gender, religion, age, disability, political beliefs, sexual orientation, and marital or family status. (Not all prohibited bases apply to all programs.) Many materials can be made available in alternative formats for ADA clients. To file a complaint of discrimination, write USDA, Office of Civil Rights, Room 326-W, Whitten Building, 14th and Independence Avenue, SW, Washington, DC 20250-9410 or call 202-720-5964.
Even without changes at the federal level, there are steps that states could take on their own to make the CBD market safer. States with broad marijuana legality or CBD-only measures could mandate the calibration and regulation of testing labs, and use them to conduct safety testing. They could fund research into the benefits, dosing, and drug interactions of CBD through their public university systems. Medical boards could redouble efforts to educate physicians in what research exists regarding medical marijuana in all its incarnations, so that doctors are prepared to prescribe and manage these medications as they become available.
For most people with epilepsy, diagnosis sets off a gauntlet of trial-and-error attempts to find the right medication. The process is tortuous, with seizures alternately dying down and flaring up while side effects— fatigue, nausea, liver damage, and more—develop without warning. This is partly due to the fact that “epilepsy” is actually a broad category that includes a number of distinct seizure disorders. About 30 medications approved by the U.S. Food and Drug Administration are currently used to treat these conditions, and when a person first begins having seizures, there is often much tinkering with combinations and dosages. I spent years battling side effects like vomiting, dizziness, drowsiness, and severe headaches, which were alleviated only by yet another prescription medication. Parents who endure enough sleepless nights caring for a sick child can become desperate for a cure.
Pain management improves a patient’s quality of life throughout all stages of cancer. Through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists, the mechanisms of cannabinoid-induced analgesia have been analyzed.[Level of evidence:1iC] The CB1 receptor is found in the central nervous system (CNS) and in peripheral nerve terminals. CB2 receptors are located mainly in peripheral tissue and are expressed in only low amounts in the CNS. Whereas only CB1 agonists exert analgesic activity in the CNS, both CB1 and CB2 agonists have analgesic activity in peripheral tissue.[48,49]